A Disputes Tribunal claim against Southern Cross Health Insurance (SCHI) over a declined ADHD assessment has raised a policy-wording question with reach beyond the individual file: how “specialist” benefit definitions apply when assessments are delivered by supervised trainees or telehealth providers, at a point when New Zealand is broadening who can diagnose ADHD.
A Waikato criminal barrister, who asked not to be identified, lodged the claim after Southern Cross declined to reimburse $1,000 for an ADHD assessment carried out by telehealth provider Psychiatry NZ, according to RNZ. The assessment was performed by a doctor training toward psychiatry registration and signed off by registered psychiatrist Dr Han Chung Lim, RNZ reported. Southern Cross categorised the session as a GP visit and contributed $65.
Chief sales and marketing officer Regan Savage told RNZ the policy covered psychiatrist consultations only where the provider held vocational registration as a psychiatrist. “In this case, the provider was not registered as a psychiatrist, so the claim did not meet the benefit criteria,” Savage said. He added that Southern Cross was “not currently considering changes to enable cover for GP consultations under the psychiatrist consultations benefit.” The barrister, who said he would donate the sum to ADHD NZ if successful, told RNZ that “SCHI’s approach limits, rather than improves access across the board.”
The dispute turns on how the Medical Council of New Zealand classifies scopes of practice. Vocational registration is permanent specialist registration allowing independent practice, while doctors in the general scope are typically resident medical officers and those in vocational training, some working under supervision. RNZ reported the assessing doctor held a general scope of practice, which the council distinguishes from being a GP.
The registration threshold is not unique to Southern Cross. UniMed, which trades as Accuro, ties its mental health benefit to consultations with a psychiatrist registered under the psychiatry scope with the Medical Council of New Zealand, among other registered provider categories, in its 2025 plan wording. That indicates registration-based benefit criteria feature in other insurers’ policies rather than being a single insurer's position.
That design is meeting a shifting care model. From Feb. 1, 2026, GPs and nurse practitioners working within their area of practice can diagnose ADHD and start stimulant treatment for adults, following decisions by Medsafe and Pharmac. The change increases the range of clinicians assessing ADHD without necessarily aligning with the vocational-registration threshold used in specialist insurance benefits. Demand for treatment has risen sharply. The number of people initially dispensed a funded ADHD medicine in New Zealand increased approximately 140%, from around 30,000 in 2020 to more than 72,000 in 2024, according to bpac New Zealand, citing Ministry of Health data. Pharmac has said it expects the prescribing change to increase demand further.
Southern Cross describes itself as New Zealand’s largest health insurer, reporting net membership of 951,808 as at June 30, 2025, approximately 60% of the health insurance market by customer numbers, and payment of over 68% of the value of all health insurance claims nationally. It reported a record 3.8 million claims in the year to June 2025, a 16% volume increase, and said it applied policy terms consistently across members. Its scale means benefit-definition decisions affect a large share of insured New Zealanders. In March 2026, Southern Cross told RNZ that ADHD and autism remained covered as neurodevelopmental conditions, reversing an earlier position that had grouped them under a mental health exclusion.
The case arrives amid increased complaint activity. In the year to June 30, 2025, the Insurance & Financial Services Ombudsman Scheme (IFSO Scheme) received 4,293 approaches and accepted 600 disputes for investigation, a 25% increase, with 29% relating to life, health, or disability insurance. The barrister pursued the Disputes Tribunal rather than the IFSO Scheme, which is free to consumers. Policy wording is also facing statutory change. The Contracts of Insurance Act 2024 requires consumer insurance contracts, including health policies, to be worded and presented clearly, and requires insurers to make information such as claims-acceptance rates publicly available; it comes into force by November 2027 at the latest. That backdrop places benefit-definition drafting under closer view.
The Disputes Tribunal’s jurisdiction increased to $60,000 from Jan. 24, 2026. Its referees have regard to the law but are not bound to give effect to strict legal rights or obligations, deciding on the substantial merits and justice of each case; hearings are private, parties are generally not legally represented, and appeal rights are limited. A ruling here would therefore be unlikely to bind other insurers, though it may inform how benefit criteria are communicated at booking and how supervised or telehealth services are assessed. RNZ did not report a hearing date. Details reflect information available as of July 3, 2026, and figures marked “approximately” or cited as reported should be verified against primary sources.
